City Therapeutics (CTY) investor relations material

Company overview and business model

• Clinical-stage biotech developing RNAi therapeutics to silence disease-relevant proteins; platform combines trigger engineering, tissue-selective delivery and genetics-led target selection.

• Pipeline targets thromboembolic disease with CITY-FXI, Stargardt disease and geographic atrophy with CITY-RBP4, and chronic-disease anemia with CITY-TFR2; all remain early clinical or preclinical.

• Platform uses AI/ML trigger design, GalNAc liver delivery and proprietary LRP1 ligands intended for ocular, CNS and adipose tissues; goal of one to two IND or IND-equivalent filings annually.

• Revenue to date comes from Bausch + Lomb and Biogen collaboration research; no product sales, approved products or commercial sales capability yet.

• Bausch + Lomb and Biogen collaborations advance ocular and CNS programs; partners may select candidates and assume development, manufacturing and commercialization responsibilities.

Financial performance and metrics

• Collaboration revenue was $13.6M in FY2025 vs. $2.8M in FY2024; R&D expense was $58.4M vs. $25.7M, and net loss was $58.5M vs. $27.8M.

• H1 2026 collaboration revenue was $6.4M vs. $5.6M H1 2025; R&D expense was $46.3M vs. $24.4M, and net loss was $53.4M vs. $24.3M.

• Accumulated deficit was $142.5M and cash, cash equivalents and restricted cash were $172.1M as of June 30, 2026; estimated preliminary unaudited cash and cash equivalents were $141.9M as of September 30, 2026.

• H1 2026 net cash used in operations was $43.2M; financing provided $101.0M, primarily from $99.5M of Series B proceeds.

• Estimated cash plus IPO proceeds is expected to fund operations into late 2028, based on current operating assumptions.

Use of proceeds and capital allocation

• Estimated net proceeds are $158.3M at the assumed $18.00 midpoint, or $182.7M if the underwriters exercise the option in full.

• Planned allocations: ~$30M for CITY-FXI, ~$20M for CITY-RBP4 and ~$40M for CITY-TFR2 clinical development.

• ~$70M planned for the City Platform, including CITY-002 and CITY-C02 and other preclinical candidates; remainder for working capital and general corporate purposes.

• Management may also use proceeds for complementary in-licenses, acquisitions or investments; no such transaction commitments were in place as of the prospectus date.